Key result
Carbon biosensor simultaneously measures iPSC-cardiomyocyte contraction and electrophysiology for drug testing.
A novel carbon-based biosensing platform enables simultaneous measurement of contraction and electrophysiology in iPSC-cardiomyocyte monolayers for disease modeling and drug testing.
Enables dual monitoring in iPSC-cardiomyocyte models; leaves open clinical translation for disease modeling and drug testing.
model of drug-induced cardiac arrhythmia was established to further validate the platform for disease modeling and drug testing.
No takes yet. Share an insight, caveat, or question.
Dou et al. (2022) studied this question. A carbon-based biosensing platform simultaneously measured contraction and electrophysiology of iPSC-cardiomyocyte monolayers, validating its use for disease modeling and drug testing.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: